Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RSB expands US market for VBR (vertebral body replacement) tech:

This article was originally published in Clinica

Executive Summary

The US FDA has given RSB Spine the market go-ahead to expand the indication of its InterPlate vertebral body replacement (VBR) system by allowing the product to be used without supplemental fixation. Under the new indication, the device can be used in patients where a less invasive, anterior approach is selected, in conjunction with a standalone implant. The Cleveland, Ohio firm said that compared to use with posterior supplemental fixation, the patient will recover more rapidly, and hospitals will realise "significant" cost savings. It added that marketing submissions for cervical and lumbar interbody indications are expected to follow, as well as new product designs based on the InterPlate platform.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel